Navigation Links
Simplest therapeutic regimen found less effective against HIV

Antiretroviral therapy for treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection has improved steadily since the advent of combination therapy in 1996//. More recently, new drugs have been approved, offering added dosing convenience and improved safety profiles, while some previously popular drugs are being used less often as their drawbacks become better defined. Resistance testing is used more commonly in clinical practice and interactions among antiretroviral agents and with other drugs have become more complex. New government guidelines recommend against starting AIDS patients on a popular treatment combination, due to concerns that using two similar drugs can rapidly lead to treatment-resistant strains of HIV.

Therapeutic regimen that combines Videx and Viread with so-called "non-nuke" drugs like Sustiva is one of several treatment groupings that have led to the dramatic turn around against AIDS. In comparison to a litany of pills that HIV patients have to swallow to keep the virus under control, Videx and Viread, are a lot simpler to use, as they have to be taken just once a day.

However, recent studies have shown that HIV quickly grows resistant to the drugs when all three are used at once, possibly because Videx and Viread attack the disease in a like-minded fashion, and so, the Department of Health and Human Services is urging newly diagnosed patients to relinquish therapies that specifically combine these three. The new ‘Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents’ have been published, dated October 6, 2005.

Dr. Roy Gulick, an HIV specialist who helped establish the new guidelines, states that when two similar drugs are used together, they tend to mimic each other and fail. Despite falling short initially, Gulick said that the combination could still be used if other options prove unsuccessful. The new guidelines reflect the broad choice in AIDS treatment, listing the pr os and cons for each, while suggesting that doctors and patients pick a regimen that best fits their needs.

While at present there are more than 20 HIV drugs that fall under four broad categories, with an almost infinite number of combinations, the best regimens suggested are those that attack the disease from different angles.
'"/>




Related medicine news :

1. Tetanus causing toxin has therapeutic properties
2. Mice model to study bacterial therapeutic pathway
3. Hormone regimen and how recently used may determine cancer risk
4. Protective regimen for acute Graft-versus-host disease
5. Distraction therapy found very effective in postoperative patients
6. Antioxidants found in chocolates
7. Hidden influenza virus protein found
8. Scientists found ancient Human Germ Killer
9. Chewing gum found to increase brainpower
10. Ulcer causing bug found in stored food
11. Antioxidants found in chocolates
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... CO (PRWEB) , ... January 17, 2017 , ... ... protection and financial planning assistance to families and business professionals throughout central Colorado, ... to regional homeless families. , The Aurora Warms The Night organization is committed ...
(Date:1/17/2017)... ... 2017 , ... Livionex, Inc., a Silicon Valley healthcare company focused on treating ... its dental gel that shows significant reduction in plaque levels and gum inflammation and ... was conducted at the Beckman Laser Institute at UC Irvine and has been published ...
(Date:1/17/2017)... Cranbury, NJ (PRWEB) , ... January 17, 2017 ... ... television personality, and breast cancer survivor Sandra Lee as keynote speaker for the ... Miami Beach, Florida. , In making the announcement, PER® president, Phil Talamo, said, ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... private companies and ranked among the top US security companies for consecutive years, ... This announcement brings a year-long independent board nomination process to a close ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global ... a new agreement as part of a long-term extension of their media partnership. The ... airing of some of the sport’s premier events exclusively on FloWrestling.com as well as ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global artificial pancreas devices system market to ... Global Artificial Pancreas Devices System Market 2016-2020, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:1/17/2017)... , Jan. 17, 2017 Paragon Bioservices received ... product development services for a variety of ... medical product development activities. The IDIQ mechanism ... pool for task order awards up to $159 ... in manufacturing and process development of biopharmaceuticals, is ...
(Date:1/17/2017)... 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... in a Phase 3 clinical trial comparing the efficacy ... in the prevention of hepatic veno-occlusive disease (VOD) in ... (HSCT) who are at high risk or at very ... will be conducted across approximately 100 medical centers in ...
Breaking Medicine Technology: